{"title":"Role of Dipstick (Leucocyte Esterase Reagent Strips) in the Rapid Bedside Diagnosis of Spontaneous Bacterial Peritonitis","authors":"Sumairaa Ashai, S. Ashraf, M. Srivastava","doi":"10.37881/1.713","DOIUrl":"https://doi.org/10.37881/1.713","url":null,"abstract":"Objectives: To evaluate the dipstick in the rapid bedside diagnosis of spontaneous bacterial peritonitis (SBP) and avoid delay in initiation of antibiotic therapy and evaluate the prevalence of SBP by a conventional method. \u0000Methods: A prospective analysis was done on inpatients and OPD patients with cirrhotic ascites at Jaipur Golden Hospital Delhi, India. The study included 110 consecutive patients with cirrhotic ascites. The patients were divided into 2 groups those with the polymorph nuclear leucocytes (PMNs) >250/mm3 on cell count (positive result) and those with PMNs <250/mm3 (Negative results) and were then compared to the dipstick results. The results were used to find the sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of the rapid dipstick method for the diagnosis of SBP. In addition, the data was used to calculate the prevalence of SBP in our hospital. \u0000Results: A total number of 110 patients with cirrhotic ascites were studied who were presented to the Jaipur Golden Hospital, New Delhi, India with the complaint of abdominal distension. A total of 20 patients were diagnosed with SBP by the manual cell count method which is considered a gold standard for the diagnosis of SBP, and 90 patients were diagnosed as non-SBP. We re-diagnosed these 20 patients with SBP with a dipstick method, the dipstick method showed a positive result for 18 patients (90%) and a negative result for 2 patients (10%). \u0000Conclusion: In the SBP group, the dipstick showed 18 true positives and 2 false negatives. In the non-SBP group of 90 patients, the dipstick method showed negative results in all the patients with no positive results. Thus, the dipstick showed 100% true negatives with 0% false positives. The prevalence of SBP in patients with cirrhotic ascites in a hospital was found at 18.2%.","PeriodicalId":383954,"journal":{"name":"NeuroPharmac Journal","volume":"102 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"115608376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Literature review of 10 plants products for their anti-inflammatory, antioxidant, immunomodulatory, and antiviral properties","authors":"Medhat Farag, A. Pathan, Nawaf Aldoaij","doi":"10.37881/1.632","DOIUrl":"https://doi.org/10.37881/1.632","url":null,"abstract":"The global health pandemic of coronavirus disease (Covid-19) did not have specifically approved medication for the treatment. To maintain the human immunity power by natural remedies is the only way to prevent coronavirus infection. We designed a study protocol by selecting 10 natural plant active constituents that were claimed by traditional and investigational ways to have anti-inflammatory, antioxidant, immunomodulatory, and antiviral properties. We will analyze these selected 10 plants' active constituents by molecular docking analysis. This article is a literature review of selected 10 plants products including Coffea Arabica, Curcuma longa, Glycyrrhiza glabra, Zizyphus vulgaris, Sisymbrium irio, Borago officinalis, Althaea officinalis, Malva sylvestris, Cordia Latifolia, and Adhatoda vasica for their anti-inflammatory, antioxidant, immunomodulatory, and antiviral properties.","PeriodicalId":383954,"journal":{"name":"NeuroPharmac Journal","volume":"28 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"115492192","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Ponesimod oral therapy for the treatment of relapsing forms of multiple sclerosis in adults and its precautions in cardiovascular disease patients","authors":"M. Alrouji","doi":"10.37881/1.633","DOIUrl":"https://doi.org/10.37881/1.633","url":null,"abstract":"The ponesimod oral therapy was approved in March 2021 by the United States Food and Drug Administration for relapsing forms multiple sclerosis (MS). Ponesimod is a sphingosine 1-phosphate (S1P) receptor 1 modulator that acts selectively as an anti- inflammatory agent and provides a suitable microenvironment for the function of the other neuroprotective agents. Ponesimod is contraindicated in patients who in the last 6 months, have experienced myocardial infarction, unstable angina, stroke, transient ischemic attack (TIA), decompensated heart failure requiring hospitalization, or Class III or IV heart failure. Also contraindicated in patients who have the presence of Mobitz type II second-degree, third-degree atrioventricular (AV) block, sick sinus syndrome, or sino-atrial block, unless the patient has a functioning pacemaker. This article briefs the information about dosage, precautions and warnings required in cardiovascular disease patients before initiation of ponesimod oral therapy.","PeriodicalId":383954,"journal":{"name":"NeuroPharmac Journal","volume":"35 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126377771","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The anticancer mechanism of human antimicrobial peptide LL-37","authors":"Aqeel Ahmad, M. Fawaz","doi":"10.37881/1.635","DOIUrl":"https://doi.org/10.37881/1.635","url":null,"abstract":"Human antimicrobial peptides LL-37 have a variety of medicinal uses. It has been portrayed that this peptide has robust tumoricidal action in a range of malignancies, particularly ovarian cancer, lung cancer, breast cancer, prostate cancer, pancreatic cancer, malignant melanoma, and squamous cell carcinoma of the skin. It exhibits substantial anticancer action against a range of cancers, including colon cancer, gastric cancer, hematologic malignancy, and oral squamous cell carcinoma (OSCC), in comparison. In this review, we explored in depth the anticancer mechanism of action of LL-37 in numerous sorts of cancer. We have shown how LL-37 impedes colon cancer by eliciting caspase-independent apoptosis. LL-37, in addition, has been noticed to boost tumor-suppressive bone morphogenetic protein signaling in gastric cancer cells via restricting the proteasome, which has been previously reported. In this research, we investigated how DNA methylation interferes with the activity of the human CAMP (Cathelicidin antimicrobial peptide gene) promoter and, as a result, acts as a tumor inhibitor in mouth squamous cell carcinoma. Additionally, how LL-37 inhibits cancer cell development in hematologic malignancy has been explored through caspase-independent but Ca2+/calpain- and AIF-dependent processes.","PeriodicalId":383954,"journal":{"name":"NeuroPharmac Journal","volume":"193 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"133017369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Tahreem Kausar, Z. Azad, Sadaf Anwar, S. Shahid, M. A. Kausar
{"title":"Application of natural antioxidants for the formulation of functional meat products","authors":"Tahreem Kausar, Z. Azad, Sadaf Anwar, S. Shahid, M. A. Kausar","doi":"10.37881/1.636","DOIUrl":"https://doi.org/10.37881/1.636","url":null,"abstract":"There is growing interest in finding healthier meals that offer more than just nutritional benefits. Meat and meat products are consumed all over the world, so it is possible to use them as matrices to make sure that people get enough bioactive components from their food. Besides extending the meat product's shelf-life and improving its composition (by integrating antioxidant molecules), it could also help people stay healthy by lowering lipid oxidative products. In this review, we look at whether developing and eating functional meat products is a viable method for improving meat composition and stability and reducing the oxidative consequences associated with the consumption of meat intake. The inclusion of plant bioactive compounds and antioxidants in meat products should protect the composition and quality of functional meat and meat products as well as the customers' health status. The key plant components with antioxidant capabilities employed in the composition of functional meat products will be discussed in this review.","PeriodicalId":383954,"journal":{"name":"NeuroPharmac Journal","volume":"38 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"129737898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Application of da Vinci robots in the surgery of selected human cancers","authors":"Yusuf Jamal, F. Al-Khodairy","doi":"10.37881/1.634","DOIUrl":"https://doi.org/10.37881/1.634","url":null,"abstract":"The discovery of da Vinci surgical systems significantly contributed to cancer surgeries worldwide, however, the clinical and oncological outcomes are still debatable. Many retrospective studies have highlighted the advantage of robotic surgery over laparoscopic or open surgical procedures for various cancers, however, more multicentered, coordinated, random clinical trials must be conducted to outline the specific advantages of da Vinci robots. They have been widely used in cancer surgeries, however, higher operative cost and comparable oncological outcomes with laparoscopic approaches further forced manufacturers to come up with affordable and efficient specialized robotic surgery systems. Nevertheless, robotic surgery using da Vinci robots has been widely accepted for hysterectomy and prostatectomy over the laparoscopic procedure and this review briefly discusses da Vinci robots in the surgery of various human cancers and their clinical outcomes.","PeriodicalId":383954,"journal":{"name":"NeuroPharmac Journal","volume":"52 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127288189","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Nidhi Sharma, S. Akhtar, Mohammad Kalim Ahmad Khan
{"title":"Bioplastics advances and their role in the management of plastic pollution","authors":"Nidhi Sharma, S. Akhtar, Mohammad Kalim Ahmad Khan","doi":"10.37881/1.620","DOIUrl":"https://doi.org/10.37881/1.620","url":null,"abstract":"Bioplastics are a type of plastic which are natural and renewable. These are made from raw materials such as sugarcane, corn starch, wood, wastepaper, fats, bacteria, algae. Bioplastics are eco-friendly as they can decompose back into carbon dioxide. Reduction of greenhouse gases through reduced carbon footprint occurs by the usage of renewable resources. In contrast to petrochemical plastics, bioplastics production is around 80% which is less than carbon dioxide. Bioplastics have been used as attractive materials for biomedical applications due to their physicochemical, biological, and degradation properties. Due to the widespread use of bioplastics, they are essential materials. Biowaste products should be designed correctly for the benefit of the environment and the utilization of these products. In composting and an anaerobic digestion infrastructure, a part of biorefineries, technology is beneficial. Enhanced production of plastics across the globe has been added more waste pollution. Recycling plastic waste is one solution to the increased plastic pollution, but it alone is not the only one. Decreased usage of fossil-based plastics is vital in the aspect of sustainability. This study aims to review the recent advances of bioplastics and their possible implications for controlling and managing plastic pollution.","PeriodicalId":383954,"journal":{"name":"NeuroPharmac Journal","volume":"77 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134371759","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Protective effect of Majoon Muṣaffī-i-Khūn (MMK) in cyclophosphamide-induced thrombocytopenia in male Sprague Dawley rats","authors":"Rukhsar Basheer, N. Jahan, J. Ahmad","doi":"10.37881/1.619","DOIUrl":"https://doi.org/10.37881/1.619","url":null,"abstract":"Aim of the study: To evaluate the efficacy of Majoon Muṣaffī-i-Khūn (MMK) in cyclophosphamide-induced thrombocytopenia in male Sprague Dawley rats. \u0000Material and Methods: Thrombocytopenia was induced by administration of Cyclophosphamide (25 mg/kg, 3 days, SC). Simultaneously, the animals were treated with MMK (300 and 600 mg/kg) orally and continued for three weeks. After completion of treatment, blood samples were collected by retro-orbital puncture and analyzed for WBC, RBC, Hb, and platelet counts, with bleeding and clotting time. MMK insignificantly increased the platelets, WBC, RBC, and Hb with a significant decreased in bleeding (p<0.001; p<0.05) and clotting times (P<0.01, P<0.001) which was altered by cyclophosphamide. \u0000Results: The results demonstrated that MMK improved platelet counts, clotting, and bleeding time as well as restored the altered level of WBC, RBC, and Hb. \u0000Conclusion: Based on the above results it can be concluded that the hydroalcoholic extract of MMK may have the potential to normalize the blood composition effectively.","PeriodicalId":383954,"journal":{"name":"NeuroPharmac Journal","volume":"78 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"117008362","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Onasemnogene Abeparvovec-xioi: World’s most expensive and approved therapy for spinal muscular atrophy","authors":"A. Pathan, V. Bairagi","doi":"10.37881/1.612","DOIUrl":"https://doi.org/10.37881/1.612","url":null,"abstract":"On May 24, 2019, the U.S. Food and Drug Administration approved Onasemnogene Abeparvovec-xioi (Zolgensma), the first gene therapy approved to treat children less than two years of age with spinal muscular atrophy (SMA), the most severe form of SMA and a leading genetic cause of infant mortality. It is priced in the United States at $2.1m (£1.6m; €1.9m) the world’s most expensive drug. Children with SMA experience difficulty performing essential functions of life. Most children with this disease do not survive past early childhood due to respiratory failure. Patients with SMA now have another treatment option to minimize the progression of SMA and improve survival. This review summarized the clinical guidelines for the Onasemnogene Abeparvovec-xioi use and may be useful to healthcare professionals.","PeriodicalId":383954,"journal":{"name":"NeuroPharmac Journal","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"128697555","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"COVID-19 in the Shaqra, Saudi Arabia: prevalence and prevention strategies","authors":"A. Pathan, A. Alshahrani, Feras Almarshad","doi":"10.37881/1.531","DOIUrl":"https://doi.org/10.37881/1.531","url":null,"abstract":"Coronavirus disease 2019 (COVID-19) is a respiratory tract infection caused by a newly emergent coronavirus, SARS-CoV-2, that was first recognized in Wuhan, China, in December 2019. In the Shaqra, the total number of COVID-19 confirmed cases reported was 183 and recovered cases was 148 with 03 reported mortalities till the 11 August 2020.\u0000In Shaqra, there was a 73 % increase in the COVID-19 confirmed cases in June 2020 as compared to May 2020 and 273 % and 200 % increase in the COVID-19 confirmed cases in July 2020 as compared to May and June 2020 respectively. The highest number of COVID-19 confirmed cases reported in May, June and July 2020 was 12, 07 and 22 respectively. Multiple precautionary steps were taken to prevent the spread of Coronavirus disease 2019 (COVID-19) in Saudi Arabia by the many government agencies.","PeriodicalId":383954,"journal":{"name":"NeuroPharmac Journal","volume":"13 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2020-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134419693","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}